MS patients rate their injection experience: kesimpta vs ocrevus

NCT ID NCT06668324

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study surveyed 134 adults with multiple sclerosis who were starting treatment with either Kesimpta or the newer subcutaneous (under-the-skin) version of Ocrevus. The goal was to compare how patients felt about their first injection, including any pain, redness, swelling, or itching at the injection site. Results will help understand which treatment might offer a better starting experience for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ofatumumab (Kesimpta) and ocrelizumab subcutaneous (Ocrevus SC)
What this could lead to: If successful, this could help doctors and patients choose between these two MS treatments based on real-world injection experiences.
What could go wrong: This is a small, completed survey study, not a treatment trial. It only measures patient-reported reactions, not long-term effectiveness or safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Novartis Investigative site

East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.